INMD — InMode Ltd.

Summary of InMode Ltd. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $103.9 million, up from $97.9 million in Q4 2024.
• Full Year 2025 Revenue: $370.5 million, a 6% decrease compared to 2024.
• International Sales: Record revenue in Europe for Q4, with international sales totaling $48.5 million, representing 47% of total sales and a 38% increase year-over-year.
• Gross Margins: GAAP gross margins were 78%, down from 79% in 2024; non-GAAP gross margins remained at 79%.
• Operating Expenses: GAAP operating expenses rose significantly to $55.3 million in Q4 and $205.6 million for the full year, an increase of 110.5% year-over-year.
• Earnings Per Share: GAAP diluted EPS was $0.42 for Q4 and $1.43 for the full year, down from $1.14 and $2.25 in 2024, respectively. Non-GAAP diluted EPS for Q4 was $0.46, compared to $0.42 in Q4 2024.
• Cash Position: As of December 31, 2025, cash and equivalents totaled $555.3 million, with $127.4 million returned to shareholders through share repurchases.

2. Strategic Updates and Business Highlights

• Leadership Changes: Appointed Michael Dennison as President of North America and unified operations across the U.S. and Canada.
• Sales Force Restructuring: Segmented sales teams focusing on aesthetic and wellness markets, with a dedicated team for the Envision platform.
• Product Innovation: Launched CO2 laser platforms in 2025 and planned to introduce two new platforms in 2026, including a Pico laser and a combined Morpheus technology with Erbium YAG laser.
• Market Position: Continued emphasis on minimally invasive technologies, which accounted for 76% of Q4 revenue.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to be between $365 million and $375 million, indicating stabilization rather than growth.
• Gross Margin Expectations: Non-GAAP gross margin projected between 75% and 77%.
• Operating Income Guidance: Non-GAAP income from operations anticipated between $87 million and $92 million; non-GAAP diluted EPS expected between $1.43 and $1.48.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: Overall revenue declined 6% year-over-year, reflecting ongoing industry challenges due to higher interest rates and softer demand in the aesthetic space.
• Operating Expenses Surge: Significant increase in operating expenses, particularly in sales and marketing, which impacted profitability.
• Market Conditions: Demand in North America remains below historical levels, and the overall aesthetic market has not fully recovered from the economic slowdown.
• Margin Pressure: Anticipated lower gross margins due to new laser product introductions and increased costs associated with sourcing products from external suppliers.

5. Notable Q&A Insights

• Signs of Recovery: Management noted early signs of stabilization in patient activity and consumable sales, with a slight increase in procedures and declining interest rates potentially improving purchasing conditions.
• Strategic Alternatives: The Board is exploring strategic alternatives to enhance company value, including ongoing discussions with Bank of America.
• Product Launch Contributions: New product launches in 2026 are expected to contribute positively, although the saturated laser market may limit margins.
• Market Dynamics: The shift towards noninvasive treatments was noted, with competitive pressures from lower-cost options affecting the demand for higher-priced minimally invasive procedures.
• R&D Investment: Increased investment in R&D is planned for 2026, particularly for clinical studies in women's health, which may impact overall spending but is seen as crucial for long-term growth.

This summary encapsulates the key points from InMode's Q4 2025 earnings call, highlighting both the company's achievements and the challenges it faces moving forward.